Abstract
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Related Books
Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features
Ricin Toxin
The Pharmaceutical Scientist Guide to Solution Kinetic Models Mathematical Description and Applications
Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
Postbiotics: Science, Technology and Applications
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Medical Applications of Beta-Glucan
Pharmaceuticals for Targeting Coronaviruses
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
70
7
1
